Guidelines on Good Publication Practice (GPP) for pharmaceutical companies are presented. The aim of the guidelines is to ensure that clinical trials sponsored by pharmaceutical companies are published in a responsible and ethical manner. The guidelines cover companies' responsibility to an endeavour to publish results of all studies, companies' relations with investigators, measures to prevent...

Today, most countries in the world are gearing up by innovation, seeking to increase productivity and improve their economic situation, and one of the important centers for innovative activities is the incubator centered companies. The majority of companies based in incubator centers are startups companies. Considering that the failure rate of new firms in the early years of formation is greate...

there are two major methods in predincing the pattern of share value in the stock market: fundamental analysis and technical analysis. i this study we developed a novel model for fundamental analysis of share price and validated it by predicting the behavior of phrama share price in tehran stock market. the efficiency of the fundamental method was compared with that of indicator-based technical...

We examine the role of different network capabilities of companies that influence the formation of R&D partnerships in pharmaceutical biotechnology. Strategic network capabilities, specifically centrality-based capabilities and the efficiency with which companies choose their partners, are found to facilitate the formation of new partnerships. Unlike general experience with partnering, these st...

it is commonly recognized that knowledge is the only source of core competence of environmental projects in the knowledge based companies, but the productivity rate of knowledge workers is always low. based on knowledge workers’ characteristics, in this paper, we seek to identify knowledge workers factors influencing on the environmental projects risk management success (eprm), then knowledg...

Knowledge of the parameters of drug development can greatly aid academic scientists hoping to partner with pharmaceutical companies. Here, we discuss the three major pillars of drug development-pharmacodynamics, pharmacokinetics, and toxicity studies-which, in addition to pre-clinical efficacy, are critical for partnering with Big Pharma to produce novel therapeutics.

Policy Forum I n the late 1950s, the late Democratic Senator Estes Kefauver, Chairman of the United States Senate's AntiTrust and Monopoly Subcommittee, put together the first extensive indictment against the business workings of the pharmaceutical industry. He laid three charges at the door of the industry: (1) Patents sustained predatory prices and excessive margins; (2) Costs and prices were...

The availability of pharmacogenomic data of individual patients can significantly improve physicians' prescribing behavior, lead to a reduced incidence of adverse drug events and an improvement of effectiveness of treatment. The Medicine Safety Code (MSC) initiative is an effort to improve the ability of clinicians and patients to share pharmacogenomic data and to use it at the point of care. T...